4Hof H. Developments in the epidemiology of invasive fungal infections- implications for the empiric and targeted antifungal therapy. Mycoses,2008,51:1-6.
5Fluckiger U, Marchetti O, BiUe J, et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly,2006,136:447-463.
6Peman J, Salavert M, Canton E, et al. Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag,2006, 2 : 129-158.
7Scott LJ, Simpson D. Voriconazole:a review of its use in the management of invasive fungal infections. Drugs,2007,67:269-298.
8Jansen JP, Meis JF, Blijlevens NM, et al. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curt Med Res Opin,2005,21:1535-1546.
3Edmond MB,Wallace SE,McClish DK.Nosocomial bloodstream infections in United States hospital:a three year analysis[J].Clin Infect Dis,1999,29(2):239-244.
4Edmond MB,Wallace SE,McClish DK.Nosocomial bloodstream infections in United States hospital:a three year analysis[J].Clin Infect Dis,1999,29(2): 239-244.
5Bodey GP,Mardani M,Hanna HA,et al.The epidemiology of Candida glabrata and Calldida albicans fungemia in immunocompromised patients with cancer[J].Am J Med,2002,112(5):380-385.
6Metcalf SC,Dockrell DH.Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts[J].J Infect,2007,55(4):287-299.
7Patterson TF.Advances and challenges in management of invasive mycoses[J].Lancet,2005,366(9490):1013-1025.
8Patterson TF.Advances and challenges in management of invasive mycoses[J].Lancet,2005,366(9490):1013-1025.
9Baddley W,Pappas G.Combination antifungal therapy for the treatment of invasive yeast and mold infections[J].Curr Infect Dis Rep,2007,9(6):448-456.
10Baddley W,Pappas G.Combination antifungal therapy for the treatment of invasive yeast and mold infections[J].Curr Infect Dis Rep,2007,9(6): 448-456.
